Antivirales (excluidos los antirretrovirales)

Prusoff, 1954, Microbiological activities of iodoorotic acid and iodouridine, Proc. Soc. Exp. Biol. Med., 85, 567, 10.3181/00379727-85-20953 Bauer, 1963, Prophylactic treatment of small pox contacts with N-Methylisatin beta-thiosemicarbazone (compound 33T57, Marboran), Lancet, 35, 494, 10.1016/S0140-6736(63)90230-7 De Clercq, 2004, Antiviral drugs in current clinical use, J. Clin. Virol., 30, 115, 10.1016/j.jcv.2004.02.009 Flint, 2004 Ingrand, 2003, Huraux. Chimiothérapie antivirale, 101 Whitley, 2005, Herpes simplex encephalitis: children and adolescents, Semin. Pediatr. Infect. Dis., 16, 17, 10.1053/j.spid.2004.09.007 Kimberlin, 2005, Herpes simplex virus infections in neonates and early childhood, Semin. Pediatr. Infect. Dis., 16, 271, 10.1053/j.spid.2005.06.007 Huraux, 2003, Herpes simplex virus, 161 Hodson, 2005, Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials, Lancet, 365, 2105, 10.1016/S0140-6736(05)66553-1 Imbert-Marcille, 2005, La prise en charge biologique des infections à cytomégalovirus chez le sujet immunodéprimé : quelles recommandations en 2005?, Virologie, 9, 339 De Clercq, 2005, Acyclic nucleoside phosphonates: a key class of antiviral drugs, Nat. Rev. Drug Discov., 4, 928, 10.1038/nrd1877 Lada, 2004, In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir, Antivir. Ther., 9, 353, 10.1177/135965350400900311 Lai, 2005, A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B, Gastroenterology, 129, 528, 10.1016/j.gastro.2005.05.053 Chang, 2005, A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients, Gastroenterology, 129, 1198, 10.1053/j.gastro.2005.06.055 Marcellin, 2004, Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B, N. Engl. J. Med., 351, 1206, 10.1056/NEJMoa040431 Zoulim, 2004, Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?, Antivir. Chem. Chemother., 15, 299, 10.1177/095632020401500602 Feld, 2005, Mechanism of action of interferon and ribavirin in treatment of hepatitis C, Nature, 436, 967, 10.1038/nature04082 Graci, 2004, Challenges for the development of ribonucleoside analogues as inducers of error catastrophe, Antivir. Chem. Chemother., 15, 1, 10.1177/095632020401500101 Pawlotsky, 2004, Antiviral action of ribavirin in chronic hepatitis C, Gastroenterology, 126, 703, 10.1053/j.gastro.2003.12.002 Lunel, 2003, Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen, J. Hepatol., 39, 826, 10.1016/S0168-8278(03)00402-1 Carrat, 2004, Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial, JAMA, 292, 2839, 10.1001/jama.292.23.2839 McHutchison, 2006, The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice, J. Hepatol., 44, 411, 10.1016/j.jhep.2005.12.001 Hayden, 2004, Pandemic influenza: is an antiviral response realistic?, Pediatr. Infect. Dis. J., 23, S262, 10.1097/01.inf.0000144680.39895.ce Moscona, 2005, Neuraminidase inhibitors for influenza, N. Engl. J. Med., 353, 1363, 10.1056/NEJMra050740 Canard, 2005, Les perspectives offertes par la biologie structurale à haut débit dans le domaine des médicaments antiviraux, Virologie, 9, 257 De Clercq, 2005, Antiviral drug discovery and development: where chemistry meets with biomedicine, Antiviral Res., 67, 56, 10.1016/j.antiviral.2005.05.001